Search | OpenScholar

Search results

1500 results found

Effects of Gocovri (Amantadine) Extended Release Capsules on Non-Motor Symptoms in Patients with Parkinson's Disease and Dyskinesia. Neurol Ther. 2021 Jun;10(1):307-320. doi: 10.1007/s40120-021-00246-3

Publication: Journal Article

Mehta, SH, R Pahwa, CM Tanner, RA Hauser, and R Johnson. 2021. “Effects of Gocovri (Amantadine) Extended Release Capsules on Non-Motor Symptoms in Patients With Parkinson’s Disease and Dyskinesia. Neurol Ther. 2021 Jun;10(1):307-320. Doi: 10.1007/S40120-021-00246-3”. Neurol Ther.

Solriamfetol for Excessive Daytime Sleepiness in Parkinson's Disease: Phase 2 Proof-of-Concept Trial. Mov Disord. 2021 Oct;36(10):2408-2412. doi: 10.1002/mds.28702. Epub 2021 Jun 30. PMID: 34191352.

Publication: Journal Article

Videnovic, A, AW Amara, C Comella, PK Schweitzer, H Emsellem, K Liu, AL Sterkel, et al. 2021. “Solriamfetol for Excessive Daytime Sleepiness in Parkinson’s Disease: Phase 2 Proof-of-Concept Trial. Mov Disord. 2021 Oct;36(10):2408-2412. Doi: 10.1002/Mds.28702. Epub 2021 Jun 30. PMID: 34191352.”. Mov Disord.

Effect of Urate-Elevating Inosine on Early Parkinson Disease Progression: The SURE-PD3.Randomized Clinical Trial. JAMA. 2021 Sep 14;326(10):926-939. doi: 0.1001/jama.2021.10207. PMID: 34519802.

Publication: Journal Article

Hauser, RA, Parkinsons Study Group SURE-PD3 Investigators, and . 2021. “Effect of Urate-Elevating Inosine on Early Parkinson Disease Progression: The SURE-PD3.Randomized Clinical Trial. JAMA. 2021 Sep 14;326(10):926-939. Doi: 0.1001/Jama.2021.10207. PMID: 34519802.”. JAMA.

Cenci MA, Riggare S, Pahwa R, Eidelberg D, Hauser RA. Dyskinesia matters. Mov Disord 2020;35:392-396.

Publication: Journal Article

“Cenci MA, Riggare S, Pahwa R, Eidelberg D, Hauser RA. Dyskinesia Matters. Mov Disord 2020;35:392-396.”. 2020. Mov Disord.

Carbidopa and Levodopa Extended Release Capsules (Rytary®) in Patients with and without Troublesome and Non-Troublesome Dyskinesia. J Parkinsons Dis 2020;10:915-925.

Publication: Journal Article

Hauser, RA, L Zeitlin, S Fisher, and R D’Souza. 2020. “Carbidopa and Levodopa Extended Release Capsules (Rytary®) in Patients With and Without Troublesome and Non-Troublesome Dyskinesia. J Parkinsons Dis 2020;10:915-925.”. J Parkinsons Dis.

Use, maintenance and dose effects of cognitive speed of processing training in Parkinson's disease. Int J Neurosci 2017;127:841-848.

Publication: Journal Article

Valdes, EG, ML O’Connor, EY Uc, RA Hauser, R Andel, and JD Edwards. 2017. “Use, Maintenance and Dose Effects of Cognitive Speed of Processing Training in Parkinson’s Disease. Int J Neurosci 2017;127:841-848.”. Int J Neurosci.

Randomized Trial of Preladenant, Given as Monotherapy, in Patients with Early Parkinson Disease. Neurology 2017;88:2198-2206.

Publication: Journal Article

Stocchi, F, O Rascol, RA Hauser, S Huyck, A Tzontcheva, R Capece, TW Ho, et al. 2017. “Randomized Trial of Preladenant, Given As Monotherapy, in Patients With Early Parkinson Disease. Neurology 2017;88:2198-2206.”. Neurology.

Factors associated with falling in early, treated Parkinson's disease: The NET-PD LS1 cohort. J Neurol Sci 2017;377:137-143.

Publication: Journal Article

Chou, KL, JJ Elm, CL Wielinski, DK Simon, MJ Aminoff, CW Christine, GS Liang, RA Hauser, L Sudarsky, and . 2017. “Factors Associated With Falling in Early, Treated Parkinson’s Disease: The NET-PD LS1 Cohort. J Neurol Sci 2017;377:137-143.”. J Neurol Sci.

ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson Disease (EASE LID Study): A Randomized Clinical Trial. JAMA Neurol 2017;74:941-949.

Publication: Journal Article

Pahwa, R, CM Tanner, RA Hauser, SH Isaacson, PA Nausieda, DD Truong, P Agarwal, et al. 2017. “ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson Disease (EASE LID Study): A Randomized Clinical Trial. JAMA Neurol 2017;74:941-949.”. JAMA Neurol.

ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson's Disease (EASE LID 2 Study): Interim Results of an Open-Label Safety Study. J Parkinsons Dis 2017;7:511-522.

Publication: Journal Article

Hauser, RA, R Pahwa, CM Tanner, W Oertel, SH Isaacson, R Johnson, L Felt, and MJ Stempien. 2017. “ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson’s Disease (EASE LID 2 Study): Interim Results of an Open-Label Safety Study. J Parkinsons Dis 2017;7:511-522.”. J Parkinsons Dis.